Stryker Corporation $SYK Stock: Patron Partners LLC Trims Stake

Patron Partners LLC cut its stake in shares of Stryker Corporation (NYSE:SYK – Free Report) by 81.3% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,271 shares of the medical technology company’s stock after selling 5,521 shares during the quarter. Patron Partners LLC’s holdings in Stryker were worth $350,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of SYK. State Street Corp boosted its stake in Stryker by 1.2% in the 2nd quarter. State Street Corp now owns 15,532,565 shares of the medical technology company’s stock worth $4,903,772,000 after purchasing an additional 183,400 shares in the last quarter. Wellington Management Group LLP increased its stake in Stryker by 0.6% during the 2nd quarter. Wellington Management Group LLP now owns 8,167,185 shares of the medical technology company’s stock valued at $2,571,357,000 after purchasing an additional 45,478 shares in the last quarter. Bank of America Corp DE bought a new stake in Stryker during the 2nd quarter valued at about $1,404,284,000. Royal Bank of Canada increased its stake in Stryker by 6.5% during the 1st quarter. Royal Bank of Canada now owns 3,273,232 shares of the medical technology company’s stock valued at $1,075,552,000 after purchasing an additional 199,863 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Stryker by 21.8% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,689,376 shares of the medical technology company’s stock worth $846,723,000 after buying an additional 481,175 shares during the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Wall Street Analyst Weigh In

SYK has been the topic of several analyst reports. TD Cowen dropped their target price on shares of Stryker from $298.00 to $290.00 and set a “hold” rating on the stock in a research note on Friday, October 30th. Royal Bank Of Canada reduced their price target on shares of Stryker from $420.00 to $375.00 and set an “outperform” rating for the company in a research report on Friday, October 30th. Barclays reduced their price target on shares of Stryker from $375.00 to $365.00 and set an “overweight” rating for the company in a research report on Friday, October 30th. Wells Fargo & Company decreased their price objective on shares of Stryker from $418.00 to $348.00 and set an “overweight” rating for the company in a report on Wednesday, September 9th. Finally, Robert W. Baird lowered their price objective on Stryker from $385.00 to $334.00 in a research report on Friday, October 30th. Twenty-one analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $343.77.

View Our Latest Report on Stryker

Stryker Trading Down 1.0%

Shares of SYK stock opened at $309.91 on Friday. Stryker Corporation has a 12-month low of $267.00 and a 12-month high of $389.33. The company has a current ratio of 2.18, a quick ratio of 1.30 and a debt-to-equity ratio of 0.60. The firm’s 50 day moving average is $295.66 and its 200 day moving average is $321.39. The stock has a market capitalization of $117.98 billion, a P/E ratio of 33.00, a P/E/G ratio of 2.13 and a beta of 0.78.

Stryker (NYSE:SYK – Get Free Report) last posted its earnings results on Thursday, October 29th. The medical technology company reported $3.52 EPS for the quarter, missing analysts’ consensus estimates of $3.55 by ($0.03). The company had revenue of $6.52 billion during the quarter, compared to the consensus estimate of $6.62 billion. Stryker had a return on equity of 23.74% and a net margin of 13.78%. The company’s revenue for the quarter was up 7.6% on a year-over-year basis. During the same period last year, the firm posted $3.19 EPS. Research analysts expect that Stryker Corporation will post 14.85 earnings per share for the current year.

Insider Activity

In related news, Director Ronda Stryker sold 550,000 shares of Stryker stock in a transaction on Friday, November 6th. The stock was sold at an average price of $325.32, for a total value of $178,926,000.00. Following the completion of the sale, the director owned 1,701,375 shares of the company’s stock, valued at $553,491,315. The trade was a 24.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 4.60% of the stock is currently owned by company insiders.

Stryker Company Profile

(Free Report)

Stryker is a medical technology company that develops and sells products and services for healthcare providers. Its offerings include orthopedic implants and surgical equipment, neurotechnology and spine products, and medical and surgical equipment used in hospitals and other care settings. The company’s products also include patient-handling and emergency medical equipment, as well as instruments and technologies that support surgical procedures. Stryker serves healthcare customers in the United States and internationally.

Further Reading

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK – Free Report).

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.